Big Pharma In The China Trade: Market Or Mirage?

A recent ChinaFile report makes pretty bleak reading for 'Big Pharma.' Long regarded as the next great hope for market expansion, the mirage of China keeps receding into the middle distance. Always there, always out of reach. This time the story centres on China forcing reductions in the price of key drugs, but previous disputes have involved the issuing of compulsory licences to produce generic versions of frontline treatments. Each time, the lure of market access for Western majors proves too compelling to turn back.